Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
Rank in Stocks #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
Share Price
$1.89
Last synced: 2022-12-16
Market Cap
$24.38M
Change (1 day)
8.62%
Change (1 year)
0.00%
Country
US
Trade Yumanity Therapeutics, Inc. (YMTX)

Category

Stock split history for Yumanity Therapeutics, Inc. (YMTX)
Yumanity Therapeutics, Inc. stock (symbol: YMTX) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 19, 2026.
One YMTX share bought prior to Aug 19, 2026 would equal to 0 YMTX shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
US
0 -
NL
1 x3
AU
0 -
CH